索引超出了数组界限。
[1] Ritchie RH, Abel ED. Basic mechanisms of diabetic heart
disease[J]. Circ Res, 2020, 126(11):1501-1525.
[2] Jia GH, Hill MA, Sowers JR. Diabetic cardiomyopathy: an
update of mechanisms contributing to this clinical entity[J].
Circ Res, 2018, 122(4):624-638.
[3] Nirengi S, Peres Valgas da Silva C, Stanford KI. Disruption
of energy utilization in diabetic cardiomyopathy; a mini
review[J]. Curr Opin Pharmacol, 2020, 54:82-90.
[4] Yang D, Zhang W, Zhang HY, et al. Progress, opportunity, and
perspective on exosome isolation-efforts for efficient exosomebased
theranostics[J]. Theranostics, 2020, 10(8):3684-3707.
[5] Thomou T, Ma MR, Dreyfuss JM, et al. Adipose-derived
circulating miRNAs regulate gene expression in other
tissues[J]. Nature, 2017, 542(7642):450-455.
[6] De Abreu RC, Fernandes H, Da Costa MP, et al. Native
and bioengineered extracellular vesicles for cardiovascular
therapeutics[J]. Nat Rev Cardiol, 2020, 17(11):685-697.
[7] Chong CR, Clarke K, Levelt E. Metabolic remodeling
in diabetic cardiomyopathy[J]. Cardiovasc Res, 2017,
113(4):422-430.
[8] Katayama M, Wiklander O, Fritz T, et al. Circulating exosomal
miR-20b-5p is elevated in type 2 diabetes and could impair
insulin action in human skeletal muscle[J]. Diabetes, 2019,
68(3): 515-526.
[9] Casta?o C, Kalko S, Novials A, et al. Obesity-associated
exosomal miRNAs modulate glucose and lipid metabolism
in mice[J]. Proc Natl Acad Sci U S A, 2018, 115(48):12158-
12163.
[10] Yu Y, Du H, Wei S, et al. Adipocyte-derived exosomal
mir-27a induces insulin resistance in skeletal muscle through
repression of PPARγ[J]. Theranostics, 2018, 8(8):2171-2188.
[11] Ying W, Riopel M, Bandyopadhyay G, et al. Adipose tissue
macrophage-derived exosomal miRNAs can modulate in vivo
and in vitro insulin sensitivity[J]. Cell, 2017, 171(2):372-384.
[12] Wen Z, Li J, Fu Y, et al. Hypertrophic adipocyte-derived
exosomal miR-802-5p contributes to insulin resistance in
cardiac myocytes through targeting HSP60[J]. Obesity (Silver
Spring), 2020, 28(10):1932-1940.
[13] Kobayashi Y, Eguchi A, Tempaku M, et al. Circulating
extracellular vesicles are associated with lipid and insulin
metabolism[J]. Am J Physiol Endocrinol Metab, 2018, 315(4):
E574-E582.
[14] Garcia NA, Moncayo-Arlandi J, Sepulveda P, et al.
Cardiomyocyte exosomes regulate glycolytic flux in
endothelium by direct transfer of GLUT transporters and
glycolytic enzymes[J]. Cardiovasc Res, 2016, 109(3):397-408.
[15] Li HP, Fan JH, Zhao YR, et al. Nuclear miR-320 mediates
diabetes-induced cardiac dysfunction by activating
transcription of fatty acid metabolic genes to cause lipotoxicity
in the heart[J]. Circ Res, 2019, 125(12):1106-1120.
[16] Peterson LR, Gropler RJ. Metabolic and molecular imaging of
the diabetic cardiomyopathy[J]. Circ Res, 2020, 126(11):1628-
1645.
[17] de Gonzalo-Calvo D, van der Meer RW, Rijzewijk LJ, et
al. Serum microRNA-1 and microRNA-133a levels reflect
myocardial steatosis in uncomplicated type 2 diabetes[J]. Sci
Rep, 2017, 7(1):47.
[18] Lee JE, Moon PG, Lee IK, et al. Proteomic analysis of
extracellular vesicles released by adipocytes of otsuka Long-
Evans tokushima fatty (OLETF) rats[J]. Protein J, 2015, 34(3):
220-235.
[19] Montgomery MK. Mitochondrial dysfunction and diabetes:
Is mitochondrial transfer a friend or foe?[J]. Biology (Basel),
2019, 8(2):33.
[20] Zhang H, Liu J, Qu D, et al. Serum exosomes mediate delivery
of arginase 1 as a novel mechanism for endothelial dysfunction
in diabetes[J]. Proc Natl Acad Sci U S A, 2018, 115(29):
E6927-E6936.
[21] Wang X, Huang W, Liu G, et al. Cardiomyocytes mediate
anti-angiogenesis in type 2 diabetic rats through the exosomal
transfer of miR-320 into endothelial cells[J]. J Mol Cell
Cardiol, 2014, 74:139-150.
[22] Hu J, Wang S, Xiong Z, et al. Exosomal Mst1 transfer from
cardiac microvascular endothelial cells to cardiomyocytes
deteriorates diabetic cardiomyopathy[J]. Biochim Biophys
Acta Mol Basis Dis, 2018, 1864(11):3639-3649.
[23] Marwick TH, Ritchie R, Shaw JE, et al. Implications of
underlying mechanisms for the recognition and management
of diabetic cardiomyopathy[J]. J Am Coll Cardiol, 2018,
71(3):339-351.
[24] Lyu L, Wang H, Li B, et al. A critical role of cardiac fibroblastderived
exosomes in activating renin angiotensin system in
cardiomyocytes[J]. J Mol Cell Cardiol, 2015, 89(Pt B):268-
279.
[25] Yang J, Yu XF, Xue F, et al. Exosomes derived from
cardiomyocytes promote cardiac fibrosis via myocytefibroblast
cross-talk[J]. Am J Transl Res, 2018, 10(12):4350-
4366.
[26] Zou T, Zhu M, Yc M, et al. MicroRNA-410-5p exacerbates
high-fat diet-induced cardiac remodeling in mice in an
endocrine fashion[J]. Sci Rep, 2018, 8(1):8780.
[27] Govindappa PK, Patil M, Garikipati V, et al. Targeting
exosome-associated human antigen R attenuates fibrosis and
inflammation in diabetic heart[J]. FASEB J, 2020, 34(2):2238-
2251.
[28] Li J, Salvador AM, Li G, et al. Mir-30d regulates cardiac
remodeling by intracellular and paracrine signaling[J]. Circ
Res, 2021, 128(1):e1-e23.
[29] Chaturvedi P, Kalani A, Medina I, et al. Cardiosome mediated
regulation of MMP9 in diabetic heart: role of mir29b and
mir455 in exercise[J]. J Cell Mol Med, 2015, 19(9):2153-
2161.
[30] Prattichizzo F, Matacchione G, Giuliani A, et al. Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential
as nano-diagnostics and nano-therapeutics in type 2 diabetes
mellitus and its cardiovascular complications[J]. Theranostics,
2021, 11(3):1031-1045.
[31] Perdomo L, Vidal-Gómez X, Soleti R, et al. Large extracellular
vesicle-associated rap1 accumulates in atherosclerotic
plaques, correlates with vascular risks and is involved in
atherosclerosis[J]. Circ Res, 2020, 127(6):747-760.
[32] St?pień E?, Durak-Kozica M, Kamińska A, et al. Circulating
ectosomes: determination of angiogenic microRNAs in type 2
diabetes[J]. Theranostics, 2018, 8(14):3874-3890.
[33] Pofi R, Giannetta E, Galea N, et al. Diabetic cardiomiopathy
progression is triggered by miR122-5p and involves
extracellular matrix: a 5-year prospective study[J]. JACC
Cardiovasc Imaging, 2021, 14(6):1130-1142.
[34] Tao L, Huang X, Xu M, et al. Value of circulating miRNA-21
in the diagnosis of subclinical diabetic cardiomyopathy[J].
Mol Cell Endocrinol, 2020, 518:110944.
[35] Wang X, Gu H, Huang W, et al. Hsp20-mediated activation
of exosome biogenesis in cardiomyocytes improves cardiac
function and angiogenesis in diabetic mice[J]. Diabetes, 2016,
65(10):3111-3128.
[36] Gan L, Xie D, Liu J, et al. Small extracellular microvesicles
mediated pathological communications between dysfunctional
adipocytes and cardiomyocytes as a novel mechanism
exacerbating ischemia/reperfusion injury in diabetic mice[J].
Circulation, 2020, 141(12):968-983.
[37] Balbi C, Vassalli G. Exosomes: beyond stem cells for cardiac
protection and repair[J]. Stem Cells, 2020, 38(11):1387-1399.
[38] Barile L, Lionetti V, Cervio E, et al. Extracellular vesicles
from human cardiac progenitor cells inhibit cardiomyocyte
apoptosis and improve cardiac function after myocardial
infarction[J]. Cardiovasc Res, 2014, 103(4):530-541.
[39] Huang G, Garikipati V, Zhou Y, et al. Identification and
comparison of hyperglycemia-induced extracellular vesicle
transcriptome in different mouse stem cells[J]. Cells, 2020,
9(9):2098.
[40] Lin Y, Zhang F, Lian XF, et al. Mesenchymal stem cell-derived
exosomes improve diabetes mellitus-induced myocardial
injury and fibrosis via inhibition of TGF-β1/Smad2 signaling
pathway[J]. Cell Mol Biol, 2019, 65(7):123-126.